Business
Dimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout
Australia-based Dimerix Limited (ASX: DXB) announced a non-dilutive loan facility of AUD 34 million (USD 23.9 million) with a syndicate of Australian and US...
Superluminal raises USD 60m Series B to take rare obesity drug into Phase I
Boston-based Superluminal Medicines has closed an oversubscribed USD 60 million Series B financing round to advance its lead small-molecule melanocortin-4...
ENA expands antiviral nasal spray INNA-051 into asthma patients with grant backing
Australia-based ENA Respiratory has received AUD 2.98 million (USD 1.9 million) from Biointelect Venturer to fund the first study of its INNA-051 antiviral...
Cipla joins Keytruda biosimilar race with Qilu deal
India-based Cipla Limited (BSE: 500087; NSE: CIPLA) has secured exclusive US commercialization rights for QL2107, a biosimilar to pembrolizumab (Keytruda),...
Thryv expands SGK1 platform into neurodegeneration with Spanish academic license
Montréal-based Thryv Therapeutics Inc. has licensed an exclusive, worldwide patent and know-how rights to a structurally distinct class of SGK1 inhibitors...
AbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart
AbbVie (NYSE: ABBV) completed its acquisition of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per share in cash for a total equity value of...
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal
Medicus Pharma Ltd. (Nasdaq: MDCX) has licensed worldwide rights to Pfizer's PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate (ADC)...
Servier secures option to Luxna's XNA chemistry platform for neurological ASO programs
Servier has expanded its research collaboration focused on Luxna Biotech Co., Ltd's XNAs Technology platform. The France-based pharmaceutical giant has...
Menarini puts up EUR 726M for Euro rights to Gan & Lee’s biweekly GLP-1
China-based Gan & Lee Pharmaceuticals (SSE: 603087) has licensed European rights to bofanglutide (GZR18), its biweekly glucagon-like peptide-1 receptor...
ARPA-H backs Waterfall Scientific-led mRNA manufacturing platform with up to USD 54.5m
Worcester, Massachusetts-based Waterfall Scientific has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to lead a six-company...
GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate
GSK has agreed to pay USD 110 million upfront for exclusive rights to develop and commercialize HMPL-A830, a pre-clinical antibody-targeted therapy...
TScan restructures around in vivo TCR-T, pauses Phase III hematology program
Waltham, Massachusetts-based TScan Therapeutics (Nasdaq: TCRX) announced a major restructuring that will shift the company away from near-term development...
Boehringer Ingelheim licenses Owkin's K Pro AI platform and immunology data
Boehringer Ingelheim has licensed K Pro, the agentic AI Scientist platform developed by New York and Paris-based Owkin, along with multimodal patient data...
CytoDyn bags another USD 16.5m in PIPE deal to support CCR5-targeted leronlimab
Vancouver, Washington-based CytoDyn Inc. (OTCQB: CYDY) closed a USD 16.5 million private placement to sustain clinical operations and advance its...
Biocytogen grants Qilu non-exclusive license to preclinical VHH antibody for neuroscience
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has granted Qilu Pharmaceutical Co., Ltd. a non-exclusive license to a...
The AllSci Brief
Free, systematic R&D and deal news. Daily.